Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Investor Presentation (March 2025)
27 slides from Aurobindo Pharma's investor presentation, March 2025
Slide 1: Aurobindo Pharma Limited Corporate Presentation
Aurobindo Pharma Limited Corporate Presentation March 2025 For internal use only
Slide 2: Table of Content
Table of Content Company Overview 03 Company Overview Business Highlights 12 Business Highlights Financial Summary 33 Financial Summary Key Levers for Sustained Growth 23 Key Levers for Sustained Growth Environment, Health Safety 25 Environment, Health & Safety 2
Slide 3: Company Overview
Company Overview 3
Slide 4: Company Snapshot
Company Snapshot #1 #2 #10 #150+ Largest Generic Pharma Largest listed Indian Ranks amongst the Top 10 Countries with Company in the US Pharma Company Generic companies in 8 export presence (by Rx dispensed)* (by FY24 revenue from countries of Europe (in FY24) operations) FY24 Global revenue: US$ 3.
Slide 5: Company Vision
Company Vision Vision Philosophy Main Pillars ✔ Global Leadership & Access To become a leading and Committed to ✔ Successful Innovation in admired global pharma Healthier Life Process Chemistry company, ranked within the ✔ Cost Effective & Affordable top 25 by 2030 5
Slide 6: Leading Global generic player
Leading Global generic player Total Revenue (US$ Mn) EBITDA (US$ Mn) Net Profit (US$ Mn) Geographical Revenue Mix (%) 706 3,504 383 11% 41% 354 195 89% 1,344 59% FY14 FY24 FY14 FY24 FY14 FY24 FY14 FY24 International Domestic Business Mix Total ANDA Filings Employee Base^ US DMFs – Filling Status 6%
Slide 7: Track record of execution
Track record of execution 1986 1988 1992 1994 2007 2010 Year of Started operation Commenced • Initial Public Offering Acquired formulations Commenced operations of Incorporation with a single API Exports • Started formulations facility in US (AuroLife) and SEZ Unit VII and AuroLife, manufacturing un
Slide 8: Acquisition- Successful Track Record of Integration (1/2)
Acquisition- Successful Track Record of Integration (1/2) Year Target Value Geography Rationale/Synergy Completed acquisition of Silicon 2013 - India • Building capability in Penem based formulations manufacturing Lifesciences • Access to 7 countries in Western Europe with an established Certain com
Slide 9: Acquisition- Successful Track Record of Integration (2/2)
Acquisition- Successful Track Record of Integration (2/2) Year Target Value Geography Rationale/Synergy • Entry into Domestic market by acquiring Veritaz business. 2022 Domestic formulations business of INR 171 Cr India • Veritaz caters anti-infective and pain-management therapeutic Veritaz Healthca
Slide 10: Manufacturing Prowess
Manufacturing Prowess Finished dosage formulations (FDF) units Active Pharmaceutical Ingredients (API) units PORTUGAL CHINA Generis Non-antibiotics, Orals Aurovitas Taizhou Orals INDIA USA Unit III FDF units in India API Units in India Non-antibiotics, Orals Eugia SEZ (former Unit XVI) Apitoria 1 (f
Slide 11: R&D Capabilities- Investing In The Future
R&D Capabilities- Investing In The Future • Development of a complex portfolio of finished dosage forms with higher entry barrier in orals, liquids, topicals, biosimilars, nasal, and parenteral products for global markets is a major priority for the upcoming years • Depot injections, Peptide injecta
Slide 12: Business Highlights
Business Highlights 12
Slide 13: Well diversified business presence
Well diversified business presence Growth Markets • 12% CAGR over FY20-24 • Strong presence in Canada with a robust portfolio of 150+ registered products Europe ARV • Received first product approval for China market • 5% CAGR over FY20-24 from Indian facility • Filed over 1,100 ARV dossiers for regi
Slide 14: US Business - Overview
US Business - Overview Product portfolio Top generic pharma company in US* #1 By Prescriptions dispensed Presence across generics 62 Products launched US (orals, injectables and OTC) and branded Oncology in FY24 2 Manufacturing units ANDA Filing details • Orals facility at Dayton, New Jersey Europe
Slide 15: US Business - Segment highlights
US Business - Segment highlights USA Orals Branded Injectables OTC US Specialty & Injectables • 6.4% of US revenue in FY24 • 64.4% of US revenue in FY24^ • 23.7% of US revenue in FY24 • 5.5% of US revenue in FY24# • Filed 31 ANDAs with USFDA in • Portfolio of seven marketed FY24 • 170 approved ANDAs
Slide 16: Europe Business - Overview
Europe Business - Overview Strong foothold in Existing commercial presence Europe Operations in 10 countries with Ranks among the top 10 generics Covered through distributors full fledged Pharmacy, Hospital US Leading generic and Tender sales infrastructure 8 companies in countries in company with c
Slide 17: Growth Markets Business - Overview
Growth Markets Business - Overview US Canada China Mexico UAE Acquired branded products business of Viatris in India Thailand Europe Indonesia. The deal has been closed on 15-Dec-23 Indonesia Colombia Brazil South Africa Strong performance in key markets driven by Growth Markets Key current markets
Slide 18: ARV Business - Overview
ARV Business - Overview Global Presence Registrations Global Tenders The Future US Supplied lifesaving Filed over 1,100 ARV Focus on global Leveraging scale to ARVs to ~3 Mn HIV dossiers for tenders floated by maintain affordable patients in more than registrations across Multi-Lateral pricing and r
Slide 19: API Business - Overview
API Business - Overview Large-scale manufacturing capabilities Among the largest API 52% Wide portfolio of Antibiotic manufacturers in the of APIs for formulations 13 US and Non-Antibiotic APIs Installed API capacity country manufactured in-house API business carved out as Apitoria Pharma for greate
Slide 20: Financial Summary
Financial Summary 20
Slide 21: Financial Summary (1/2)
Financial Summary (1/2) Revenue Gross Profit 3,504 2,500 62% 3,264 3,347 3,153 2,009 1,981 3,098 1,888 1,691 60% 2,783 2,000 1,790 1,638 60% 58% 1,500 59% 58% 56% 57% 57% 1,000 54% 55% 500 52% 0 50% FY20 FY21 FY22 FY23 FY24 9M FY25 FY20 FY21 FY22 FY23 FY24 9M FY25 Revenue (US$ Mn) Gross Profit (US$
Slide 22: Financial Summary (2/2)
Financial Summary (2/2) R&D Expenditure Earnings Per Share 400 6.7% 8% 6.1% 5.7% 55.03* 54.16 300 5.1% 5.1% 6% 48.32 47.26* 44.25 4.1% 204 213 176 179 32.90 200 143 4% 135 100 2% 0 0% FY20 FY21 FY22 FY23 FY24 9M FY25 FY20 FY21 FY22 FY23 FY24 9M FY25 R&D Spend (US$ Mn) R&D Spend % of Sales EPS (INR)
Slide 23: Key Levers for Sustained Growth
Key Levers for Sustained Growth 23
Slide 24: Key levers for Sustained Growth
Key levers for Sustained Growth 50bn+ capacity Expanding manufacturing footprint PEN-G Backward integration to build resilient supply chain Indonesia Extending geographical presence with growth markets acqn. 853 ANDAs Well diversified filed product portfolio Future ready with expansion into biosimil
Slide 25: Environment, Health & Safety
Environment, Health & Safety 25
Slide 26: Environment, Health & Safety
Environment, Health & Safety Goals achieved in FY24 16% 64% 100% Reduction in carbon 14% Co-processing of hazardous Reuse/recycle of non- footprint (as per SBTi – Renewable energy share waste hazardous waste WB2C) Community Care ⮚ Established Skill Development Centres in rural areas, offering traini
Slide 27: Thank You
Thank You For more information, contact: ir@aurobindo.com; cc@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 1551 | 6672 5005 27
Aurobindo Pharma — Investor Presentation (March 2025) on 6ix